Navigation Links
Momentum of Stem cell research impeded by legal challenges

California in the year 2005 planned to begin stem cell research in the state with the approval of 61% of voters passing the Proposition 71. But the legal challenges have impeded the initiative. //

The officials now say that it would take spring 2007 before the project will be initiated. Zach Hall, president of the California Institute for Regenerative Medicine, told his board of directors that it would commence the project as soon as possible.

The lawsuit has prevented the agency from borrowing $3 billion which will be used by the agency for issuing as research grants over the next 10 years.

But the institute is bestowed with $50 million in temporary private funds from philanthropies and wealthy individuals to start training stem cell researchers.

Zach Hall also suggested another $2 million for collaborating with other scientific organizations, including international meetings and conferences.

So far this project is been fueled by a $3 million state loan and a $5 million philanthropic gift, but that money is set to run out in June.

The professor said that Universities and other Research institutions have to rely on their own funding sources to begin their stem cell research programs.

Robert Birgeneau, an institute board member and chancellor of University of California Berkeley, said his campus could significantly expand research programs if the initial funds were released by the government.

Stem cell research is a controversial topic to discuss because it involves the destruction of many embryos. But it is believed that this research could yield treatments for diseases like Parkinson's, Alzheimer's and insulin-dependent diabetes.

The lawsuit alleges that the managers of the stem cell agency are not state officials and many of them have conflicts of interest.

The judge though declined to throw out the suits, ruled out all the challenges that have blocked the progress
'"/>




Page: 1 2

Related medicine news :

1. Global Momentum for Smoke-Free Indoor Environments at Tipping Point
2. Stem cell research- now Nobel Laureates join the debate
3. Spouses and other partners lower blood pressure says new research
4. Ecstasy shrinks brain!!-researchers unveil the secrets of MDMA.
5. Stem cell research
6. Gene researchers make Malaria-resistant mosquito
7. Novel research on liver cancer
8. Space research leads to needle-free blood tests
9. SARS research confirms link to animals
10. New turn in stem cell research
11. Calcium Supplementation May Not Actually Prevent colon cancer say researchers
Post Your Comments:
(Date:5/16/2008)...unking the Myth 25 Years Later: An AIDS Vaccine is...May 16 /PRNewswire-USNewswire/ -- Twenty-five year...onsiderable advances in addressing,the AIDS pandem...out HIV,perhaps more than any other pathogen, and...other viral diseases combined. But this progress i...
(Date:5/16/2008)...n to Visit Omaha to Rally Residents to Eat Right, ...eir Diets, OMAHA, Neb., May 16 /PRNewswire/ -- Th...of different fad diets -- which seem to go in and ...t, long-term success has been,slim. Two out of thr...esidents -- remain overweight or obese., A new ca...
(Date:5/16/2008)...MOUTH MEETING, Pa., May 16 /Xinhua-PRNewswire-Firs...) one of China,s leading marketing and,distributio...he Company,will present at the following conferenc...eld in seven cities in China. David Gao, Chie... scheduled to present on May 19, 2008, at 4:40 ...
(Date:5/16/2008)...ue expands natural killer cells in cord blood more...Day News) A treatment that uses natural killer (N...ffectively destroys human leukemia cells in mice, ...percent to 85 percent human acute lymphocytic leuk...lls in test mice with aggressive human leukemias, ...
Breaking Medicine News(10 mins):Health News:World AIDS Vaccine Day 2008 2Health News:World AIDS Vaccine Day 2008 3Health News:World AIDS Vaccine Day 2008 4Health News:Message to Nebraska Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Nebraska Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:BMP Sunstone Announces Participation in May Investor Conferences 2Health News:New Therapy Kills Human Leukemia Cells in Mice 2
...ts may be beneficial in preventing severe long-ter...resently there exists no effective treatment for t...isability is most likely to appear. The Children...ing in the Journal of Neuroscience, and conducted...
...C, Wednesday to demand more funds for cancer resea...traveled to the rally in Washington.// She said, "...hes so many people, but on the other hand, it's em...eople willing to volunteer, give their time and th...
...nesday reported having updated the warning label o...sers about the higher risk of blood clots from it....missioned study revealed that drug users faced two... lungs compared to women taking traditional birth-...
...rpose of a sunscreen lotion as well as offers prot...searchers//, well on the threshold of a discovery;...athway that will prevent the fair skin people from...ainst cancer. Study's lead author, Dr. David E. F...
Other Medicine News:Health News:Vitamin Shots to Combat MS Pain 2Health News:Contraceptive Patch Carries Risk of Blood clots 2
(Date:5/16/2008)... NEW YORK, May 16 /- Pulmo ...ounced details of the methodology and,purpose of i...ar Imaging,technology for the diagnosis of Pulmona... will be carried out by the Pulmo BioTech subsidia...s: "Phase I Study of the Use,of PulmoBind for Mole...
(Date:5/16/2008)... BRIDGEWATER, N.J., May 16 /- Data fr...ower mean baseline hemoglobin (Hb) levels,and the ...e effect of,restrictions on reimbursement for eryt...atients on the nation,s blood supply, will be pres... (ASCO) Annual Meeting later this,month. The meeti...
(Date:5/16/2008)...ktar,s Technology Enables First-Ever PEGylation of...ted Therapeutic Activity, SAN CARLOS, Calif., May...(Nasdaq: NKTR ) announced initial results today f...ecan. The data shows significant,anti-tumor activi...tudy,also demonstrates that Nektar,s small molecul...
(Date:5/16/2008)...Single Molecule with Dual Mechanism May Offer Nove...ure Management, NEW ORLEANS, May 16 /PRNewswire-F...ator in the discovery and development of novel sma...33540, its first-in-class,Dual Acting Receptor Ant...lood pressure reductions in a Phase 2a study in pa...
Breaking Medicine Technology:Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 2Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8BioMarin to Present at the Rodman 26 Renshaw 9th Annual Healthcare Conference 1611 1Crystal Research Associates LLC Issues Executive Informational Overview 28R 29 28EIO 28R 29 29 on CEL SCI Corporation 709 1Crystal Research Associates LLC Issues Executive Informational Overview 28R 29 28EIO 28R 29 29 on CEL SCI Corporation 709 2Crystal Research Associates LLC Issues Executive Informational Overview 28R 29 28EIO 28R 29 29 on CEL SCI Corporation 709 3US government delays nanotechnology safety measures 1048 1US government delays nanotechnology safety measures 1048 2Medivation Announces Participation in Acumen BioFin Rodman 26 Renshaw 9th Annual Healthcare Conference 1605 1Medivation Announces Participation in Acumen BioFin Rodman 26 Renshaw 9th Annual Healthcare Conference 1605 2
...FirstCall/ --,Bionovo, Inc.,s lead drug candidate,...eatment of hot flashes associated with menopause.,...he company,s,double-blind, placebo- controlled, ra...50 or more moderate to severe hot flashes,per week...receiving,MF101 (5 grams/day), MF101 (10 grams/day...
...rstCall/ -- VION,PHARMACEUTICALS, INC. announced t... session at the 43rd Annual Meeting of The America...anticancer agent,Cloretazine(R) (VNP40101M) as a s...elapsed or refractory small cell lung cancer. , Th...1M) in two,separate subpopulations of small cell l...
Other Medicine Technology:Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 2Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 3Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 4Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 5Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 2Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 3Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 4
We have water perfused manometric catheters for esophageal, anorectal and vector volume diagnostic tests. All Medtronic Water Perfused Catheters are made using clear, medical grade PVC tubing. For pr
Each solid state catheter kit below is supplied with adapter cable(s) for Polygraf ID and a Manometric Calibrator.
Each solid state catheter kit below is supplied with adapter cable(s) for Polygraf ID and a Manometric Calibrator.
...dtronic offers a family of single-use products to ...or you. This single-use catheter reduces cross-con...e risk of infection and, because cleaning is elimi...have water perfused manometric catheters for esoph...
Medicine Products: